XORTX Therapeutics Financials
| XRTX Stock | USD 1.21 0.03 2.54% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.33 | 12.6987 |
|
|
Investors should never underestimate XORTX Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor XORTX Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in XORTX Therapeutics.
Net Income |
|
XORTX | Select Account or Indicator |
Understanding current and past XORTX Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of XORTX Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in XORTX Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in XORTX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XORTX Therapeutics. Check XORTX Therapeutics' Beneish M Score to see the likelihood of XORTX Therapeutics' management manipulating its earnings.
XORTX Therapeutics Stock Summary
XORTX Therapeutics competes with Cue Biopharma, Eliem Therapeutics, Inhibrx, and Molecular Partners. XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. Xortx Therapeutics is traded on NASDAQ Exchange in the United States.| Foreign Associate | Canada |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | CA98420Q2071 |
| CUSIP | 98420Q207 98420Q306 98420Q108 |
| Location | British Columbia; Canada |
| Business Address | 3710 33rd Street |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.xortx.com |
| Phone | 403 455 7727 |
| Currency | USD - US Dollar |
XORTX Therapeutics Key Financial Ratios
| Return On Equity | -0.29 | ||||
| EBITDA | (6.47 M) | ||||
| Net Income | (2.16 M) | ||||
| Cash Per Share | 1.03 X | ||||
| Debt To Equity | 0.01 % |
XORTX Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.1M | 2.3M | 17.3M | 12.3M | 5.5M | 5.0M | |
| Other Current Liab | 641.5K | 728.4K | 3.8M | 151.4K | 87.6K | 83.2K | |
| Net Debt | (7.8K) | (171.3K) | (14.8M) | (10.3M) | (3.4M) | (3.6M) | |
| Retained Earnings | (6.8M) | (8.0M) | (7.6M) | (14.1M) | (17.9M) | (17.0M) | |
| Accounts Payable | 607.4K | 305.8K | 324.0K | 1.3M | 195.8K | 186.0K | |
| Cash | 58.6K | 171.3K | 14.8M | 10.4M | 3.4M | 3.6M | |
| Net Receivables | 15.5K | 14.4K | 40.7K | 81.8K | 60.7K | 35.1K | |
| Total Liab | 1.3M | 1.0M | 4.2M | 5.4M | 825.9K | 784.6K | |
| Total Current Assets | 815.2K | 2.1M | 15.8M | 10.9M | 4.1M | 4.2M | |
| Intangible Assets | 272.4K | 234.3K | 201.0K | 199.4K | 175.3K | 189.0K | |
| Net Tangible Assets | (484.1K) | 1.0M | 16.5M | 9.2M | 10.6M | 11.1M | |
| Net Invested Capital | (160.9K) | 1.3M | 16.7M | 7.0M | 4.6M | 4.6M | |
| Net Working Capital | (484.5K) | 1.0M | 14.9M | 9.4M | 3.8M | 4.3M | |
| Other Current Assets | 741.2K | 2.1M | 1.0M | 379.6K | 560.4K | 728.6K |
XORTX Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Operating Income | (566.0K) | (1.3M) | (4.1M) | (10.7M) | (6.6M) | (6.2M) | |
| Ebit | (566.0K) | (1.3M) | (4.1M) | (10.7M) | (6.6M) | (6.2M) | |
| Ebitda | (546.1K) | (1.3M) | (4.1M) | (10.6M) | (6.5M) | (6.1M) | |
| Income Before Tax | (629.6K) | (1.3M) | (1.3M) | (7.0M) | (2.9M) | (3.0M) | |
| Net Income | (629.6K) | (1.3M) | (1.3M) | (7.0M) | (2.9M) | (3.0M) | |
| Interest Expense | 15.5K | 22.3K | 37.2K | 13.5K | 4.4K | 0.0 | |
| Income Tax Expense | 37.2K | 13.5K | 4.4K | 0.0 | (0.01) | (0.0095) | |
| Net Interest Income | (37.2K) | (13.5K) | (1.6M) | (825.4K) | 253.5K | 266.2K | |
| Research Development | 39.9K | 277.5K | 669.1K | 6.5M | 3.2M | 1.7M |
XORTX Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of XORTX Therapeutics. It measures of how well XORTX is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money XORTX Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money XORTX had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what XORTX Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (201.4K) | 112.7K | 14.7M | (3.5M) | (7.0M) | (6.6M) | |
| Free Cash Flow | (256.6K) | (742.8K) | (4.8M) | (8.9M) | (6.6M) | (6.3M) | |
| Capital Expenditures | 7.0K | 14.4K | 31.2K | 44.2K | 46.4K | 30.7K | |
| Net Income | (629.6K) | (1.3M) | (1.3M) | (7.0M) | (2.2M) | (2.3M) | |
| End Period Cash Flow | 58.6K | 171.3K | 14.8M | 10.4M | 3.4M | 3.6M | |
| Depreciation | 19.9K | 20.4K | 14.0K | 55.5K | 139.7K | 146.7K | |
| Other Non Cash Items | 1.6K | (90.2K) | 58.8K | 3.7K | (3.7M) | (3.5M) | |
| Investments | (7.0K) | (14.4K) | (39.8K) | (44.2K) | (46.4K) | (48.7K) | |
| Change To Netincome | 62.0K | 173.5K | (3.1M) | (4.5M) | (4.1M) | (3.9M) |
XORTX Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XORTX Therapeutics's current stock value. Our valuation model uses many indicators to compare XORTX Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XORTX Therapeutics competition to find correlations between indicators driving XORTX Therapeutics's intrinsic value. More Info.XORTX Therapeutics is rated first in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, XORTX Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XORTX Therapeutics' earnings, one of the primary drivers of an investment's value.XORTX Therapeutics Systematic Risk
XORTX Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. XORTX Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on XORTX Therapeutics correlated with the market. If Beta is less than 0 XORTX Therapeutics generally moves in the opposite direction as compared to the market. If XORTX Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one XORTX Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of XORTX Therapeutics is generally in the same direction as the market. If Beta > 1 XORTX Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in XORTX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various XORTX Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of XORTX Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
XORTX Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of XORTX Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of XORTX Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of XORTX Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing XORTX Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build XORTX Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.78 | |||
| Information Ratio | 0.0506 | |||
| Maximum Drawdown | 157.0 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 16.04 |
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.